Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $9.00 price objective on the stock.

Other analysts have also issued research reports about the company. Maxim Group upped their price objective on Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Roth Capital cut their price objective on Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.86.

Gain Therapeutics Trading Down 8.3%

Shares of Gain Therapeutics stock opened at $1.87 on Wednesday. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.09. The firm has a market cap of $67.23 million, a price-to-earnings ratio of -2.97 and a beta of 0.11. The business has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $1.78. Gain Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $3.19.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, equities analysts forecast that Gain Therapeutics will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

Several hedge funds have recently modified their holdings of the stock. Kovitz Investment Group Partners LLC acquired a new position in Gain Therapeutics during the first quarter valued at $91,000. Dauntless Investment Group LLC acquired a new position in Gain Therapeutics during the first quarter valued at $240,000. Marshall Wace LLP raised its position in Gain Therapeutics by 41.0% during the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after buying an additional 80,407 shares during the period. Finally, Geode Capital Management LLC raised its position in Gain Therapeutics by 2.9% during the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after buying an additional 8,251 shares during the period. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.